Oslo, Norway, 20 May 2026: Reference is made to the Annual General Meeting (the
"AGM") of Oncoinvent ASA (the "Company") earlier today where the nomination
committee's proposal for remuneration for the members of the Board was approved.

The AGM approved the following share option remuneration to the Board.

  · Chair of the Board: 1,708 share options
  · Board members: 854 share options

Share options normally vest over a four-year period as follows: no options shall
vest during the first 12 months following the date of the grant, 13/48 of the
options shall vest in the 13th month, the remaining options shall thereafter
vest in equal monthly instalments of 1/48. Options expire seven years after the
grant date.

The exercise price for this grant is NOK 46,5195 per option equal to the volume
weighted average share price (VWAP) the last day before the grant.

The following members of the Board of Oncoinvent ASA has received share options
grants, according to the terms described above:

  · Gillies O'Bryan-Tear (Chairperson of the Board) has been granted 1,708 share
options. Following the grant, he holds 26,369 shares and 5,245 share options in
Oncoinvent ASA.
  · Kari Grønås (Board member) has been granted 854 share options. Following the
grant, she holds 902 shares and 2,506 share options in Oncoinvent ASA.
  · Hilde Steineger (Board member) has been granted 854 share options. Following
the grant, she holds no shares and 2,506 share options in Oncoinvent ASA.
  · Orlando Oliveira (Board member) has been granted 854 share options.
Following the grant, he holds no shares and 2,506 share options in Oncoinvent
ASA.
  · Johan Häggblad (Board member) has been granted 854 share options. Following
the grant, he holds no shares and 1,804 share options in Oncoinvent ASA.
  · Olav Hellebø (Board member) has been granted 854 share options. In addition,
he receives an option grant equivalent to the option allocation to Board members
of Oncoinvent ASA approved by the 2025 AGM, adjusted for actual time served,
amounting to a total of 554 share options. These options are granted at an
exercise price equal to the volume weighted average share price (VWAP) on the
last trading day before the merger; both the number of share options and
exercise price have been adjusted for the previous reverse share split and
reduction of nominal value. Following these grants, he holds 2,000 shares and
1,408 share options in Oncoinvent ASA.

PDMR notifications 20 May 2026 - grant of board
options.pdf (https://mb.cision.com/Public/15728/4351019/af029f4cd62a133c.pdf)

This information is subject to the disclosure requirements pursuant to article
19 of the regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5
-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: [email protected] ([email protected])

About Oncoinvent

Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation
therapy that leverages the unique anatomy of the abdominal cavity to destroy
residual micrometastases using a single, highly localized dose of alpha
radiation. The initial clinical focus is treatment of ovarian and colorectal
cancer patients after surgical removal of the primary tumor and visible
metastases in the peritoneum, the thin membrane lining the abdominal cavity and
covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the
peritoneal cavity, keeping patients disease-free for longer than the current
standard of care and thereby also impacting overall survival. It is broadly
applicable to any cancer that spreads to the peritoneum, e.g. ovarian,
colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity,
excellent safety profile, and seamless integration into existing surgical
workflows. Oncoinvent's product is easy to use, avoids systemic delivery and
significant toxicity. It is also differentiated in being simple to manufacture,
scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers,
are highly promising, showing an excellent safety profile and meaningful signals
of efficacy. Interim data from an ongoing, randomized, controlled phase 2
ovarian cancer trial is expected in 2026. With cost-effective manufacturing,
blockbuster potential, active pharma partnership momentum, plus strong
endorsements from leading experts, Oncoinvent is built for scale and commercial
success, and is set to become the new standard for post-surgical cancer care.
The Company was founded by the originators of Algeta and Xofigo (acquired by
Bayer).
he new standard for post-surgical cancer care.\
The Company was founded by the originators of Algeta and Xofigo (acquired by\
Bayer).\